NICE recommends non-hormonal treatment for hot flushes
Abstract
The National Institute for Health and Care Excellence (NICE) has recommended a non-hormonal treatment for moderate-to-severe vasomotor symptoms caused by menopause for use on the NHS in England. In final draft guidance published on 11 March 2026, NICE approved fezolinetant (Veoza; Astellas Pharma), a 45mg tablet taken once a day, which blocks the nerve pathways in the brain […]
Fields of Study & Subjects
Menopause: Health Impacts and Treatments
Estrogen and related hormone effects
Sexual function and dysfunction studies
Publication details
- Journal / source
- Pharmaceutical journal/The pharmaceutical journal
- Publication date
- 1 January 2026
- Language
- EN